Welcome to our dedicated page for THERIVA BIOLOGICS SEC filings (Ticker: TOVX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Theriva Biologics, Inc. (TOVX) SEC filings page provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information about Theriva’s clinical-stage programs, capital structure, and corporate actions, complementing its press releases and scientific presentations.
Investors can review Form 10-K and Form 10-Q annual and quarterly reports for discussions of risk factors, research and development activities, and financial condition related to programs such as VCN-01, SYN-004 (ribaxamase), SYN-020, and the VCN-X discovery efforts. Current reports on Form 8-K describe material events, including clinical data announcements, regulatory feedback from agencies such as the European Medicines Agency, warrant inducement agreements, public offerings, and at-the-market sales agreements.
Theriva’s proxy statements on Schedule 14A outline matters submitted to stockholders, such as proposals to approve the issuance of additional common shares upon exercise of warrants issued in private placements. These documents explain voting mechanics, record dates, and the rationale for share authorization requests tied to financing transactions.
Forms related to securities offerings, such as registration statements and prospectus supplements referenced in 8-K filings, describe the terms of public offerings of common stock and warrants, as well as at-the-market programs through placement agents. Together, these filings help clarify how Theriva funds the development of its clinical pipeline.
On this page, Stock Titan pairs Theriva’s SEC filings with AI-powered summaries that highlight key points, such as changes in capital structure, new clinical or regulatory disclosures, and important risk factor updates. Real-time updates from EDGAR, along with structured access to historical filings, allow users to monitor how Theriva’s regulatory and financing profile evolves alongside its investigational therapies.
Theriva Biologics, Inc. has called a special stockholder meeting on April 9, 2026 to vote on two proposals. The main item seeks approval to issue up to 16,184,560 shares of common stock upon exercise of previously issued common stock purchase warrants at an exercise price of $0.54 per share, as required under NYSE American rules.
The company states that full cash exercise of these warrants could provide up to approximately $8.7 million in gross proceeds. As of the record date of February 27, 2026, there were 45,892,668 shares of common stock outstanding. The Board also seeks authority to adjourn the meeting if needed to obtain sufficient votes, and unanimously recommends voting in favor of both the warrant exercise and adjournment proposals.
Theriva Biologics, Inc. outlines its transformation into an oncology-focused, clinical-stage company centered on oncolytic adenovirus candidate VCN-01 (zabilugene almadenorepvec) for solid tumors, led by metastatic pancreatic ductal adenocarcinoma and retinoblastoma.
The 10-K highlights positive Phase 2b VIRAGE data in first-line metastatic pancreatic cancer, where VCN-01 plus gemcitabine/nab-paclitaxel improved overall and progression-free survival versus chemotherapy alone, with greater benefit in patients receiving two VCN-01 doses. Regulators in the U.S. and Europe granted Orphan Drug and Fast Track designations and provided guidance supporting a single pivotal Phase 3 trial using VCN-01 with gemcitabine/nab-paclitaxel.
Theriva also reports encouraging Phase 1 results for intravitreal VCN-01 in refractory retinoblastoma, including Orphan and Rare Pediatric Disease designations and a potential priority review voucher if ultimately approved. Beyond VCN-01, the company is advancing next-generation virus VCN-12 and a THERICEL suspension cell platform to scale viral manufacturing. In parallel, Theriva has de-emphasized its gastrointestinal pipeline, licensing SYN-020 globally to Rasayana Therapeutics and seeking partners for SYN-004, while retaining milestone, royalty and sublicense economics.
Theriva Biologics reported full-year 2025 results alongside a strategic licensing deal. The company licensed its Phase 2‑ready asset SYN-020 to Rasayana Therapeutics, with up to
Cash and cash equivalents were
The company recorded a 2025 net loss of
Theriva Biologics, Inc. is asking shareholders to approve the issuance of up to 16,184,560 shares of common stock upon exercise of newly issued common stock purchase warrants, a proposal tied to a warrant inducement completed on October 17, 2025. The board says approval would permit exercise of the New Warrants at a stated exercise price of $0.54 per share and could generate up to $8.7 million in gross proceeds if fully exercised for cash.
The New Warrants were issued as part of an inducement arrangement and are exercisable only after stockholder approval; they include beneficial ownership caps of 4.99% (or, at holder election, 9.99%) and typical adjustment and fundamental-transaction provisions. As of the record date there were 45,892,668 shares outstanding.
Theriva Biologics has out-licensed its SYN-020 program to Rasayana Therapeutics under an exclusive worldwide agreement. Theriva received a $300,000 upfront payment and is eligible for up to $16,000,000 in development milestones and up to $22,000,000 in sales milestones, plus tiered low- to mid-single-digit royalties on net sales and a share of sublicense revenue.
Rasayana will assume all responsibility and costs for developing and commercializing SYN-020, which has completed Phase 1 and is planned to enter Phase 2. The deal allows Theriva to focus resources on its lead pancreatic cancer program VCN-01 while retaining economic participation in any future SYN-020 success.
Theriva Biologics, Inc. was unable to convene its Special Meeting of Stockholders on February 11, 2026 because not enough shares were present to form a quorum. The meeting was intended to obtain stockholder approval for issuing up to 16,184,560 shares of common stock upon exercise of certain New Warrants under an October 16, 2025 inducement agreement.
The company plans to call a new stockholder meeting to seek this approval and will announce the date and time and send new proxy materials. Under the inducement agreement, unless investors waive the requirement, Theriva must call another meeting every 60 days until stockholder approval is obtained or the New Warrants are no longer outstanding.
Theriva Biologics, Inc.
The presentation includes forward-looking statements language under the Private Securities Litigation Reform Act of 1995, indicating that it discusses expectations and plans in addition to historical information. No new financial results or major transactions are described in this report itself; it primarily alerts investors to the availability of the updated presentation.
Theriva Biologics, Inc. reported an equity award to its senior leadership. On 01/05/2026, a reporting person who serves as director, CEO and CFO received an option grant over 475,000 shares of common stock at an exercise price of $0.241 per share.
The stock options become exercisable on a pro rata monthly basis over 36 months, starting on 02/01/2026, and are scheduled to expire on 01/04/2033 if not exercised. Following this grant, the reporting person held 475,000 derivative securities directly, aligning a portion of their compensation with the company’s future share performance.
Theriva Biologics, Inc. director John J. Monahan reported a new stock option grant. On 01/05/2026 he received stock options to buy 75,000 shares of common stock at an exercise price of $0.241 per share. The options become exercisable starting 02/01/2026 and expire on 01/04/2033. They vest on a pro rata monthly basis over 12 months, which means a portion of the options becomes available to exercise each month during the first year.
Theriva Biologics, Inc. reported an insider equity award to one of its directors. The Form 4 shows a grant of 75,000 stock options with an exercise price of $0.241 per share on 01/05/2026. These options become exercisable starting 02/01/2026 and expire on 01/04/2033. According to the footnote, the options vest on a pro rata monthly basis over 12 months, meaning the director earns a portion of the grant each month during the first year.